The vasorelaxing action of labedipinedilol-A involves endothelial cell-derived NO and eNOS expression caused by calcium influx

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 3, 2005, Pages 232-240

  Liou, Shu Fen ^a   Wu, Jiunn Ren ^a   Lai, Wen Ter ^a   Sheu, Sheng Hsiung ^a   Chen, Ing Jun ^a   Yeh, Jwu Lai ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ca2+; Cyclic GMP; Endothelium; Labedipinedilol A; Nitric oxide; Vasorelaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CALCIUM; CALCIUM ANTAGONIST; CYCLIC GMP; DIHYDROXYFUMARIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GLUTATHIONE; IRON; LABEDIPINEDILOL A; LACIDIPINE; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PEROXY RADICAL; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; BRAIN HOMOGENATE; CALCIUM TRANSPORT; CELL CULTURE; CELL DEATH; ENDOTHELIUM CELL; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING; VASODILATATION;

ANIMALS; ANISOLES; ANTIOXIDANTS; AORTA, THORACIC; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; CELL SURVIVAL; CYCLIC GMP; DIHYDROPYRIDINES; ENDOTHELIAL CELLS; ENDOTHELIN-1; FREE RADICALS; GLUTATHIONE; GUANYLATE CYCLASE; LIPID PEROXIDATION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR;

EID: 14744275191     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000154375.88283.5c     Document Type: Article

References (35)

1. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986;38:321-416.
2. Godfraind T, Salomone S. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther. 1996;10: 439-446.
3. Liang JC, Yeh JL, Wang CS, et al. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display α-/β-adrenoceptor antagonist and long acting antihypertensive activities. Bioorg Med Chem. 2002;10:719-730.
4. Liang JC, Yeh JL, Chiang LC, et al. Labedipinedilol-A: a vanilloid-based α/β-adrenoceptor blocker with calcium entry blocking and long-acting antihypertensive properties. Drug Dev Res. 2000;49:94-108.
5. Yeh JL, Liang JC, Liou SF, et al. Ventricular PKC-ε and humoral signaling in DOCA-salt rats treated with labedipinedilol-A. Drug Dev Res. 2003;59: 307-315.
6. Liou SF, Yeh JL, Liang JC, et al. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J Cardiovasc Pharmacol. 2004;44: 539-551.
7. Salomone S, Silva CL, Morel N, et al. Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:505-512.
8. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res. 1992;70: 1099-1103.
9. Berkels R, Egink G, Marsen TA, et al. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240-245.
10. Sobal G, Menzel EJ, Sinzinger H. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem Pharmacol. 2001;61:373-379.
11. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22:S1-S14.
12. Moellering D, McAndrew J, Patel RP, et al. Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase. Arch Biochem Biophys. 1998;358:74-82.
13. Moellering D, Mc Andrew J, Patel RP, et al. The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase. FEBS Lett. 1999;448:292-296.
14. Mak IT, Boehme P, Weglicki WB. Protective effects of calcium channel blockers against free radical-impaired endothelial cell proliferation. Biochem Pharmacol. 1995;50:1531-1534.
15. Napoli C, Salomone S, Godfraind T, et al. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke. 1999;30:1907-1915.
16. Yang J, Fukuo K, Morimoto S, et al. Pranidipine enhances the action of nitric oxide released from endothelial cells. Hypertension. 2000;35: 82-85.
17. Mak IT, Zhang J, Weglicki WB. Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol Res. 2002;45:27-33.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
19. Lo YC, Hsiao HC, Wu DC, et al. A novel capsaicin derivative VOA induced relaxation in rat mesenteric and aortic arteries: involvement of CGRP, NO, cGMP, and endothelium-dependent activities. J Cardiovasc Pharmacol. 2003;42:511-520.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260: 3440-3450.
21. 2-agonist activity. Drug Dev Res. 1999;47:77-89.
22. Tsuchiya M, Scita G, Freisleben HJ, et al. Antioxidant radical-scavenging activity of carotenoids and retinoids compared to alpha-tocopherol. Methods Enzymol. 1992;213:460-472.
23. 2+ channel. Naunyn Schmiedebergs Arch Pharmacol. 1995;351:40-45.
24. 2+-independent regulation of smooth muscle contraction. J Muscle Res Cell Motil. 2002; 23:47-52.
25. Sessa WC, Harrison JK, Barber CM, et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem. 1992;267:15274-15276.
26. Ding Y, Vaziri ND. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension. 1998;32: 718-723.
27. Vanhoutte PM. Calcium-entry blockers and vascular smooth muscle. Circulation. 1982;65:I11-I19.
28. ++ in coronary vessel contraction induced in vitro by noradrenaline following a beta-adrenergic block. Cardiology. 1990;35: 635-643.
29. Wang GJ, Wu XC, Chen CF, et al. Vasorelaxing action of rutaecarpine: effects of rutaecarpine on calcium channel activities in vascular endothelial and smooth muscle cells. J Pharmacol Exp Ther. 1999;289:1237-1244.
30. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85: 587-590.
31. Prasad MR, Jones RM, Kreutzer DL. Release of endothelin from cultured bovine endothelial cells. J Mol Cell Cardiol. 1991;23:655-658.
32. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2003;138:532-543.
33. Jongkind JF, Verkerk A, Baggen RG. Glutathione metabolism of human vascular endothelial cells under peroxidative stress. Free Radic Biol Med. 1989;7:507-512.
34. Fukuo K, Yang J, Yasuda O, et al. Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation. 2002;106:356-361.
35. Krenek P, Salomone S, Kyselovic J, et al. Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats. Hypertension. 2001;37:1124-1128.